Amy Schulman is an Entreprenur Partner focused on funding and founding companies in the healthcare sector. Upon joining Polaris in 2015, assumed the role of Chief Executive Officer of Arsia Therapeutics, a Polaris-backed company acquired by Eagle Pharmaceuticals (NASDAQ: EGRX) in November 2016.
In July 2015, Amy co-founded Lyndra, where she is CEO and in 2017 became CEO of Olivo Laboratories, both Polaris-backed companies. Also on behalf of Polaris, she serves as the Executive Chair of SQZ Biotech and Suono Bio and is director of Alnylam Pharmaceuticals (NASDAQ: ALNY) and Ironwood Pharmaceuticals (NASDAQ: IRWD). In addition, she serves as a director of Blue Buffalo (NASDAQ: BUFF) and the Whitehead Institute.
Prior to these roles, Amy was responsible for leading Pfizer Inc.’s (NASDAQ: PFE) $4 billion Consumer Healthcare business, which operates in 90 countries and includes well-known brands such as Advil, Centrum, and Chapstick. She also served concurrently as Executive Vice President and General Counsel of Pfizer Inc. Previously at Pfizer, Amy was SVP, President & General Manager of the infant formula and nutrition business where she was instrumental in the unit’s sale to Nestle for $11.85 billion in 2012.
Before joining Pfizer, Amy was a Partner at DLA Piper, where she was a member of the Board and Executive Policy Committees, and built and led the international law firm’s mass tort and class-action practice.
Amy is the recipient of numerous awards and distinctions including: Scientific American’s 2015 Worldview 100 List, Fierce Biotech’s 2014 Top 15 Women in Biotech, Fortune Magazine’s 2013 50 Most Powerful Women in Business, The American Lawyer’s 2013 Top 50 Innovators, and The National Law Journal’s 2013 100 Most Influential Lawyers in America.
Amy is a member of Harvard Business School’s Faculty where she serves as a Senior Lecturer and teaches legal and corporate accountability. A Phi Beta Kappa graduate of Wesleyan University, Amy earned her J.D. from Yale Law School in 1989.